BCL2 and small cell lung carcinoma: In solid tumors, we have found that venetoclax has preclinical activity in SCLC where high BCL-2 expression serves as a biomarker [22]; based on these data, an early-phase clinical trial will soon be enrolling to evaluate the combination of venetoclax and irinotecan.